The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar® (gatifloxacin 0.3%) in a NZW rabbit model

American Journal of Ophthalmology

Volumn 139, Issue 5, 2005, Pages 867-877

  Romanowski, Eric G ^a,b,c,d   Mah, Francis S ^a   Yates, Kathleen A ^a   Kowalski, Regis P ^a   Gordon, Y Jerold ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh School of Medicine   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; OXACILLIN; SODIUM CHLORIDE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLEPHARITIS; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA EDEMA; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; IRITIS; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; TOPICAL TREATMENT; TREATMENT FAILURE;

EID: 18144431291     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2005.01.021     Document Type: Article

References (11)

1. D.C. Hooper Fluoroquinolone resistance among gram-positive cocci Lancet Inf Dis 2 2002 530 538
2. M.H. Goldstein, R.P. Kowalski, Y.J. Gordon Emerging fluoroquinolone resistance in bacterial keratitis a 5-year review Ophthalmology 106 1999 1313 1318
3. R.P. Kowalski, A.N. Pandya, L.M. Karenchak An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa Ophthalmology 108 2001 1826 1829
4. M.R. Chalita, A.L. Hofling-Lima, A. Paranhos Jr, P. Schor, R. Belfort Jr Shifting trends in in vitroantibiotic susceptibilities for common ocular isolates during a period of 15 years Am J Ophthalmol 137 2004 43 51
5. F.B. Marangon, D. Miller, M.S. Muallem, A.C. Romano, E.C. Alfonso Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis Am J Ophthalmol 137 2004 453 458
6. R.P. Kowalski, L.M. Karenchak, E.G. Romanowski Infectious disease changing antibiotic susceptibility G.N. Foulks R.G. Gardler Ophthalmology clinics of North America, cornea and external disease 2003 W. B. Saunders Company Philadelphia 1 9
7. R. Mather, L.M. Karenchak, E.G. Romanowski, R.P. Kowalski 4th Generation fluoroquinolones new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 2002 463 466
8. R.P. Kowalski, D.K. Dhaliwal, L.M. Karenchak, E.G. Romanowski, F.S. Mah, D.C. Ritterband, Y.J. Gordon Gatifloxacin and moxifloxacin an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates Am J Ophthalmol 136 2003 500 505
9. R.P. Kowalski, L.M. Karenchak, Y.J. Gordon Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels Cornea 17 1998 282 287
10. D.M. Grasela Clinical pharmacology of gatifloxacin, a new fluoroquinolone Clin Infect Dis 31 Suppl 2 2000 S51 S58
11. J.M. Blondeau Fluoroquinolones Mechanism of action, classification, and development of resistance Surv Ophthalmol 49 Suppl 2 2004 S73 S78